Post by PressRelease on Jan 08, 2024 7:00am
New Press Release - ProMIS Neurosciences Issues Letter to Shareholders
Comment by
M101 on Jan 08, 2024 10:35am
At least he acknowledged two repeat concerns. "... our tight control on cash management." "Our priorities are clear: to advance PMN310 through clinical development; to increase the Company’s visibility..."
Comment by
BottomBroker on Jan 08, 2024 12:52pm
"We remain committed to advancing PMN310 through the rigorous clinical development process. Over the coming months, we will be laser-focused on completing the SAD clinical study with PMN310 and, subsequently, rolling into the Phase 1b Multiple Ascending Dose (MAD) study, subject to the availability of sufficient capital." Oh boy.....
Comment by
M101 on Jan 08, 2024 1:15pm
Yeah well that's the intentional ceiling and a forward looking statement, but why back out now? Glass half full: there is no limit this election year to the money printing for maintaining the appearance of a functioning economy.